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Statistical Methods for Targeted Clinical
Trials under Enrichment Design
Jen-Pei Liu,1,2* Jr-Rung Lin1
Background/Purpose: After completion of the Human Genome Project, disease targets at the molecular level
can be identified. Treatment for these specific targets can be developed with the individualized treatment
of patients becoming a reality. However, the accuracy of diagnostic devices for molecular targets is not perfect
and statistical inference for treatment effects of the targeted therapy is biased. We developed statistical
methods for an unbiased inference for the targeted therapy in patients who truly have the molecular targets.
Methods: Under the enrichment design, for binary data, we propose using the expectation maximization (EM)
algorithm with the bootstrap method, to incorporate the inaccuracy of the diagnostic device for detection of
the molecular targets for inference of the treatment effects. A simulation study was conducted to empirically
investigate the performance of the proposed estimation and testing procedures. A numerical example illustrates
the application of the proposed method.
Results: Simulation results demonstrated that the proposed estimation method was unbiased, with adequate
precision, and the confidence interval provided satisfactory coverage probability. The proposed testing proce-
dure adequately controlled the size with sufficient power. The numerical example showed that a statistically
significant treatment effect could be obtained when the inaccuracy of the diagnostic device was taken into
account.
Conclusion: Our proposed estimation and testing procedures are adequate statistical methods for the 
inference of the treatment effect for patients who truly have the molecular targets. [J Formos Med Assoc
2008;107(12 Suppl):S35–S42]
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As a result of recent insights into genomics and
pharmacogenomics, molecular disease targets can
be identified and utilized for treatment.1–5 At the
same time, diagnostic devices for detection of dis-
ease using state of the art biotechnology such as
microarray, polymerase chain reaction (PCR),
mRNA transcript profiling, and single nucleotide
polymorphisms, have also become possible. As a
result, treatments specific for the patients with the
identified molecular targets can be developed, and
patients benefit from the treatment without suf-
fering serious or even fatal toxicity. Consequently,
personalized medicine may finally become a 
reality.
Targeted therapy is a type of treatment that uses
drugs or other means, such as monoclonal anti-
bodies, against the identified molecular targets
that are involved in disease pathogenesis. Targeted
clinical trials are those that evaluate the efficacy
and safety of targeted therapies.6 The current 
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paradigm involves developing and evaluating a
drug or a treatment using a shot-gun approach
that may not be beneficial for most patients. On
the other hand, targeted therapy employs a guided-
missile approach to reach the molecular targets.
For targeted therapy, therefore, one must have:
(1) knowledge of the molecular targets involved
in pathogenesis; (2) a device for detection of the
molecular targets; and (3) a treatment aimed at
the molecular targets. Thus, development of tar-
geted therapies involves translation from the 
accuracy of diagnostic devices for the molecular
targets to the efficacy and safety of the treatment
modality for the patient population with the tar-
gets. Therefore, clinical trials for evaluation of tar-
geted therapies are much more complicated than
the current paradigm of clinical development. 
To address the issues of development of targeted
therapies, the United States Food and Drug Admin-
istration (FDA) issued the Draft Drug-Diagnostic
Co-development Concept Paper7 and In Vitro Diag-
nostic Multivariate Index Assays,8 in April 2005 and
July 2007, respectively.
For targeted clinical trials, in addition to the
usual inclusion criteria based on clinical signs,
symptoms, and clinical laboratory results, the pres-
ence of the molecular targets is one of the most
important inclusion criteria. The enrichment de-
sign9 is one of the designs suggested in the FDA
draft concept paper for targeted clinical trials.
Figure 1 provides a diagram for enrichment design.
Under the enrichment design, patients are screened
using the diagnostic device for identification of
the molecular targets and only those with a posi-
tive diagnosis for the molecular target are ran-
domized to receive either the targeted treatment
or the untargeted concurrent control. However,
no diagnostic test is perfect with a 100% positive
predictive value (PPV). In addition, measures for
diagnostic accuracy such as sensitivity, speci-
ficity, PPV, or negative predictive value (NPV) are
in fact estimators with variability. Thus, the treat-
ment effect of the targeted drug might be under-
estimated in the patient population that truly
has the molecular target.10 On the other hand,
binary data such as response rate is one of the
most frequently employed clinical endpoints for
evaluation of treatment effect.
Therefore, under the enrichment design, we
propose to apply the expectation maximization
(EM) algorithm11,12 with bootstrap method13 to
incorporate the uncertainty of the PPV of the 
diagnostic device for statistical inference of the
treatment effect of the targeted drugs, with re-
spect to the binary data. A simulation study was
conducted to empirically investigate the perfor-
mance of the proposed procedures in terms of
the bias and coverage probability of confidence
intervals (CI) for estimation, and size and power
for hypothesis testing. A hypothetical numerical
example constructed from real experience was
used to illustrate the application of the proposed
statistical method for the inference of the treat-
ment effect of the targeted drug in the patient
population that truly had the molecular target.
Discussion and final remarks on the statistical
inference of the targeted clinical trials are also
provided.
Materials and Methods
First, we assume that specific molecular targets
involved in pathogenesis have been identified. 
A diagnostic device available for detection of the
identified molecular target has been developed.
In addition, the diagnostic accuracy of the device
has been evaluated and has met the regulatory
All subjects 
All diagnosed at randomization
Diagnosis is − Diagnosis is +
Control group Targeted drug
R
Figure 1. Diagram for enrichment design. R= randomization.
Targeted clinical trials
J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl S37
requirements. Furthermore, this device is used
only for detection of the molecular target and
not for prognosis. We then assume that a test
drug is currently being developed for the specific
molecular targets. Following the enrichment de-
sign in Figure 1, a two-group parallel design is
considered in which the patients with a positive
result by the diagnostic device are randomized in
a 1:1 ratio to receive either the molecular targeted
test treatment (T) or a untargeted concurrent con-
trol treatment (C). We further assume that the pri-
mary efficacy endpoint is a binary variable such
as response. A binary variable has two possible
outcomes: responding or not responding to the
treatment, with some response criteria prespeci-
fied in the trial protocol. We further assume that
the sample size is sufficiently large that normal
approximation can be adequately applied.
It should be noted that the PPV of a diagnos-
tic test is an increasing function of the prevalence
of the disease.14 For a disease with a prevalence
rate > 10%, even when sensitivity and specificity
of the diagnostic device are 95%, its PPV can be
as low as 68%. As a result, under the enrichment
design, all randomized patients have a positive
diagnosis, and the proportion of patients that are
truly without the molecular targets can be quite
high. Table 1 gives the true response rate by treat-
ment and diagnostic result of the molecular tar-
get. PT+, PC+ (PT−, PC−) denotes the true unknown
response rate of test and control groups for the
patient population with (and without) the mo-
lecular target. The treatment effect in the patient
population truly with and without the molecular
targets is represented respectively as: θ+=PT+ − PC+ ,
and θ− = PT− − PC−.
The target drug is developed specifically for
the treatment of the patients that truly have the
molecular target, therefore, the targeted drug is
only effective in the patient population that truly
has the molecular targets, and is not effective or
is less efficacious in those without the targets.
Therefore, we assume that the treatment effect of
the targeted drug in the patient population that
truly has the molecular targets is greater than
that without the targets, i.e. PT+ − PC+ > PT− − PC−.
As demonstrated above, under the enrichment
design, some patients with a positive diagnostic
result may in fact not have the molecular targets.
The treatment effect obtained from the enrich-
ment design consists of two components. The
first component is the treatment effect of the tar-
get drug in the patient population that truly has
the molecular target. The second component is
the treatment effect of the targeted drug in the
patient population with a positive diagnosis, but
who do not have the target. In other words: treat-
ment effect obtained under enrichment design =
PPV(PT+ − PC+) + (1 − PPV)(PT− − PC−) < PT+ − PC+.
It follows that the difference in sample pro-
portions obtained under the enrichment design
for targeted clinical trials in fact underestimates
the true treatment effect of the target drug in 
the patient population that truly has the molec-
ular target. However, the bias decreases as PPV
increases.
There are two issues with the enrichment de-
sign. The first is that although all randomized
patients under the enrichment design have a
positive diagnosis, because the diagnostic device
is not perfect, some randomized patients do not
have the molecular targets. Therefore, the responses
of the patients to the targeted drug obtained in
the enrichment design are a mixture of two dis-
tributions: the responses of the patients who truly
have the targets and the responses of those with-
out the targets. Another issue is that the true sta-
tus for the molecular target is in fact unknown
Table 1. Response rates by treatment and diagnosis
Positive diagnosis True target condition Accuracy of diagnosis Test group Control group Treatment effect
+ + PPV PT+ PC+ PT+ − PC+
− 1 − PPV PT− PC− PT− − PC−
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and missing. To resolve these two issues and to
obtain an unbiased statistical inference for the
patients who truly have the molecular targets, we
apply the EM algorithm.11,12 This is done to ob-
tain the maximum likelihood estimator (MLE)
for the treatment effect of the targeted drug in
the patient population that truly has the targets.
In addition, we employ the bootstrap method to
estimate the standard error of the MLE obtained
from the EM algorithm.13 The PPV estimated for
the diagnostic effectiveness trials for evaluation
of the accuracy of the diagnostic device for detec-
tion of the molecular target can be used as the
initial value of the PPV for the EM algorithm. It
follows that an unbiased inference, including point
and interval estimation and hypothesis testing
for the treatment effect of the targeted drug, can
be made for the patient population that truly has
the molecular targets. Technical details and an
executive file of the Fortran program of our pro-
posed methods can be obtained from the authors
upon request.
To investigate the performance of our proposed
statistical methods, we conducted a simulation
study to empirically examine the relative bias and
coverage probability for point and interval esti-
mation, and size (type I error rate) and power for
hypothesis testing. In addition, the proposed meth-
ods are illustrated using hypothesized data con-
structed from real experience.
Results
Simulation results
Table 2 presents the simulation results for com-
parison between our proposed method and the
traditional approach without consideration of
the false-positive patients without the molecular
targets on relative bias of the point estimator and
the coverage probability of the 95% CI. As can be
seen in Table 2, the traditional approach under-
estimated the treatment effect. The relative bias
of the traditional approach ranged from −50%
when PPV was 0.5 to around −10% when PPV was
0.9. On the other hand, except for three cases for
which the absolute relative bias was between 1%
and 3%, all absolute relative bias of our proposed
estimation procedure was within 1%. The cover-
age probability of the 95% CI constructed by the
traditional approach could be as low as 60%. The
coverage probability of the 95% CI constructed
by our proposed method was always above 95%.
Therefore, with respect to estimation, our pro-
posed method outperformed the traditional ap-
proach. However, it should also be noted that the
relative bias of the traditional method decreased
and its coverage probability increased when the
PPV increased.
Table 3 provides the empirical size of the tra-
ditional method and our proposed method when
PT+=PC+. When PT+− PC+=0, the statistical inference
Table 2. Relative bias (%) and coverage probability
PPV
0.5 0.7 0.8 0.9n diff
Traditional EM Traditional EM Traditional EM Traditional EM
100 0.05 −50.3520 −0.7835 −28.7879 0.7974 −20.9639 −1.0978 −7.0919 2.7808
0.9908 0.9800 0.9858 0.9760 0.9826 0.9760 0.9808 0.9760
0.1 −50.6080 −0.9713 −30.8180 −0.9572 −20.8140 −0.8657 −10.4360 −0.4761
0.9968 0.9798 0.9934 0.9848 0.9860 0.9746 0.9842 0.9758
0.15 −50.4413 −0.7302 −29.5573 0.2144 −20.0920 −0.2561 −11.1320 −1.1958
0.8056 0.9640 0.8946 0.9580 0.9136 0.9476 0.9314 0.9462
0.2 −50.7330 −0.6837 −29.9350 −0.1267 −19.7950 0.0854 −9.8150 0.0737
0.6012 0.9654 0.8120 0.9570 0.8902 0.9584 0.9368 0.9616
Upper row = relative bias; lower row = coverage probability.
Targeted clinical trials
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for the treatment effect of the targeted drug by
the traditional and our proposed method was
unbiased. The simulation results on empirical
size given in Table 3 confirm this. The empirical
sizes of both methods were very close to the nom-
inal level of 0.05. In addition, the magnitudes of
the empirical size were independent of the PPV.
It follows that the traditional approach and our
proposed method adequately controlled the type
I error rate at the nominal level.
Table 4 gives the results for the empirical power
of the traditional approach and our proposed
method for the one-sided hypothesis of PT+ > PC+
at different values of PT+ − PC+. As demonstrated
in Table 4, the empirical power of our proposed
method was always larger than that of the tradi-
tional approach at all values of PT+ − PC+, irrespec-
tive of the magnitude of PPV. Figure 2 provides 
a comparison of power curves between the two
methods when PPV was 0.8. Table 4 and Figure 2
Table 3. Comparison of empirical sizes
PPV
n 0.5 0.7 0.8 0.9
Traditional EM Traditional EM Traditional EM Traditional EM
100 0.0518 0.0494 0.0506 0.0504 0.0492 0.0490 0.0508 0.0508
200 0.0554 0.0522 0.0502 0.0496 0.0532 0.0526 0.0514 0.0514
300 0.0492 0.0478 0.0518 0.0506 0.0494 0.0476 0.0482 0.0478
0 0.025 0.05 0.075 0.1 0.125 0.15 0.17 0.19 0.21 0.23
Difference in proportions
0
0.2
0.4
0.6
0.8
1 Traditional
EM
Po
w
er
Figure 2. Empirical power curve when PPV was 0.8.
Table 4. Comparison of empirical powers
e PPV
0.5 0.7 0.8 0.9n diff
Traditional EM Traditional EM Traditional EM Traditional EM
100 0.05 0.0698 0.1270 0.0878 0.1344 0.1028 0.1260 0.1180 0.1346
0.1 0.1218 0.4054 0.2052 0.3952 0.2662 0.3944 0.3270 0.3944
0.15 0.2336 0.7828 0.4308 0.7794 0.5382 0.7712 0.6480 0.7634
0.2 0.3794 0.9834 0.6874 0.9824 0.8202 0.9816 0.9212 0.9778
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show that our proposed method was uniformly
more powerful than the traditional approach in
assessment of the treatment effect of the targeted
drug in the patient population that truly had the
molecular targets.
Numerical examples
Herceptin® is a recombinant-DNA-derived human-
ized monoclonal antibody for the treatment of
metastatic breast cancer in patients whose human
epidermal growth factor (HER2) receptor is over-
expressed. One of the indications approved by the
US FDA is the first-line treatment of metastatic
breast cancer. The approval of this indication is
based on the evidence provided by Study 3, which
was a multicenter, randomized, open-label clinical
trial in patients with metastatic breast cancer not
previously treated with chemotherapy. The en-
richment design was employed for Study 3, in
which only patients with a staining score of 2+
or 3+ by immunohistochemistry were random-
ized to receive chemotherapy plus Herceptin®
(235 patients) or chemotherapy alone (234 pa-
tients).15 The response rates for chemotherapy
plus Herceptin® and chemotherapy alone were
45% and 29%, respectively (p < 0.001 for the 
difference between the response rates).
Based on the information provided by the US
FDA package insert for Herceptin®, we assumed
that the response rates for chemotherapy plus
Herceptin® and chemotherapy alone are 45% and
30%, respectively, in patients with metastatic breast
cancer with a staining score of 2+ or above. Based
on this assumption, we generated a hypothetic
data set of responses for 480 patients: 240 for
targeted drug and 240 for the concurrent control.
Table 5 provides the point estimates of response
rate, difference of response rates between the two
groups, and standard error and 95% CI for the
difference at various PPVs.
When PPV was 0.5, the traditional approach—
when inaccuracy of diagnostic device was not
considered—yielded estimated responses rates
of 0.375 and 0.296 for the targeted drug and
control, respectively. This gave an estimate of
0.0792 for the difference between the two groups
with a 95% CI from −0.001 to 0.167. Since the
95% CI contained 0, the observed difference in
response rates was not statistically significant
and the targeted drug failed to prove its superior
efficacy over chemotherapy alone at the 5% level.
The reason for the failure of the targeted drug was
that 50% of positive patients randomized did
not have the molecular targets. This resulted in a
−47.2% underestimation of the treatment effect
and statistical nonsignificance. On the other hand,
our proposed method provided the estimated 
response rates of 0.455 and 0.301, respectively,
for the targeted drug and the control group. The
estimated difference in response rates was 0.154,
with a relative bias of 2.7%. The 95% CI for the
difference in response rates was 0.073 and 0.244,
which did not contain 0. As a result, it can be
concluded that the efficacy of the targeted drug
was superior to that of the control group, based
on the response rate.
If PPV increased to 0.8, the traditional approach
gave the estimated response rates of 0.421 and
Table 5. Point and interval estimator of response rates
Results
PPV = 0.50 PPV = 0.80 PPV = 0.90
Traditional EM Traditional EM Traditional EM
PˆT+ 0.375 0.455 0.421 0.453 0.437 0.454
PˆC+ 0.296 0.301 0.300 0.302 0.304 0.305
PˆT+ − PˆC+ 0.079 0.154 0.121 0.151 0.133 0.149
SE 0.043 0.044 0.043 0.044 0.044 0.044
95% LCI −0.001 0.073 0.036 0.065 0.048 0.063
95% UCI 0.167 0.244 0.206 0.237 0.219 0.234
SE = standard error; LCI = lower confidence interval; UCI = upper confidence interval.
Targeted clinical trials
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0.300 for the targeted drug and control, respec-
tively. This gave an estimate of 0.121, which is an
underestimation of about −19.3%. The 95% CI for
the difference in response rate was 0.036–0.206.
Therefore, the targeted drug can be claimed effi-
cacious by the traditional approach. It should be
noted that the relative bias of the traditional ap-
proach became less severe as PPV increased. On
the other hand, the point estimates for individ-
ual response rates and difference in response rates
and 95% CI for the difference in response rates
provided by our proposed methods were not in-
fluenced by PPV.
Discussion
For a targeted clinical trial using the enrichment
design, all randomized patients must have a pos-
itive diagnosis for the molecular targets by the diag-
nostic device. However, no device has a perfect
diagnostic accuracy with 100% PPV. Therefore, a
targeted clinical trial may randomize some false-
positive patients who do not in fact have the molec-
ular target. As a result, the traditional approach
without consideration of inaccuracy of the diag-
nostic device may produce a biased inference for
the treatment effects of the targeted drug for the
patient population that truly has the molecular
target. Therefore, for the binary data, we apply
the EM algorithm with the bootstrap method to
incorporate information on the PPV for inference
of the treatment effect in the patient population
that truly has the molecular target. Simulation re-
sults and numerical examples demonstrated that
the proposed statistical method was not only un-
biased in point and interval estimation, but also
controlled the type I error rate at the nominal level
and was uniformly more powerful than the tradi-
tional method.
On the other hand, the inferential procedures
for the treatment effects of the targeted drug
based on the censored endpoints such as overall
or progression-free survival in the patients who
truly have the molecular target require further re-
search. The Bayesian method is another approach
for incorporating the uncertainty in accuracy of
the diagnostic device for the molecular target into
the inference of the treatment effects of the targeted
drug. For the Bayesian approach, one possible prior
distribution for PPV is the beta distribution. How-
ever, a study of the Bayesian approach to the in-
ference of treatment effects in targeted clinical
trials using the enrichment design is also urgently
needed.
The discrimination power of a single individ-
ual biomarker or allele is limited, therefore, a
polygenic approach with the targeted treatment
for multiple targets may be feasible for individu-
alized treatment. However, diagnostic accuracy is
one of the most important characteristics when it
comes to determining the utility of the polygenic
diagnostic device for identification of multiple
targets in targeted clinical trials using the enrich-
ment design. The reason for a negative result from
the targeted clinical trial may not be the ineffec-
tiveness of the targeted drug, but rather underes-
timation of the treatment effect because of a low
PPV, such that a large number of patients without
the molecular targets were randomized into the
targeted trial. For example, the PPV of the FDA-
approved MammaPrint® is only 0.22 for metasta-
tic disease at 5 years.16,17 Therefore, statistical
methodology on the design and analysis of drug-
device codevelopment of the polygenic approach
for multiple targets requires urgent attention.
Disclaimer
The views expressed in this article are the per-
sonal opinions of the authors and may not nec-
essarily represent the position of the National
Taiwan University and the National Health Research
Institutes, Taiwan.
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